Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or post-menopausal women between 50 and 85 years~* Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria~* CT or MRI results compatible with clinical diagnosis~* MMSE score between 10 and 24, both inclusive~* Modified Hachinski Ischemic Score \>4~* Hamilton Depression Scale score of less than or equal to 15~* Adequate visual and auditory acuity to allow neuropsychological testing~* Informed consent given by the patient and/or the next-of-kin~Exclusion Criteria:~* Gastric ulcer associated with intolerance of acetylsalicylic acid treatment~* Severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol~* Any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span.~* Patients who in the investigator's opinion, would not comply with study procedures~* Any significant neurological disease other than vascular dementia, such as Parkinson's disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis~* History of alcohol or substance abuse or dependence within the past two years~* Patients with a history of systemic cancer within the past two years~* Severe congestive heart failure or malignant, uncontrollable hypertension~* Participation in a clinical trial with an investigational drug in the past four weeks

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cerebrolysin (Type: EXPERIMENTAL): None
- 0.9% Saline Solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).